7-Hydroxy-3,4-dihydro-2(1H)-quinolinone Intermediate Manufacturer & Supplier India

7-Hydroxy-3,4-dihydro-2(1H)-quinolinone is a high-quality intermediate supplied by Vubrix Pharma Private Limited, a leading API manufacturer and exporter based in Surat, Gujarat, India. 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone is a critical intermediate in the synthesis of Aripiprazole and other CNS-active pharmaceutical compounds. This hydroxylated quinolinone derivative serves as a key building block in multi-step synthetic routes, enabling the production of high-value APIs. Vubrix Pharma manufactures this intermediate with strict quality control, ensuring consistent purity and low impurity levels required for pharmaceutical synthesis. Our optimized process delivers high yields while maintaining excellent chemical purity suitable for GMP manufacturing.

As an established 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone manufacturer in India, Vubrix Pharma supports pharmaceutical companies, formulation developers, research institutions, and global distributors with reliable supply, technical documentation, and responsive commercial support. Whether you require laboratory quantities for method development or multi-ton commercial batches for regulated markets, our team delivers material that meets stringent quality expectations.

Vubrix Pharma's 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone production is supported by validated manufacturing processes, comprehensive analytical testing, and a quality management system aligned with GMP principles and ISO 9001:2015 requirements. We understand that sourcing intermediates from India requires more than competitive pricing—it demands traceability, regulatory readiness, and a partner who responds quickly to technical and commercial inquiries.

Our 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone offering for Aripiprazole applications is designed for customers in the United States, Canada, United Kingdom, European Union, Middle East, Latin America, and Asia-Pacific regions. We provide Certificate of Analysis (COA), Material Safety Data Sheet (MSDS), and regulatory documentation packages to accelerate your qualification and procurement process.

• Key intermediate in Aripiprazole API synthesis
• Building block for other CNS-active pharmaceutical compounds
• Research and development of novel quinolinone derivatives
• Custom synthesis projects requiring quinolinone scaffolds

Vubrix Pharma manufactures 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone using a controlled, documented synthesis route developed and optimized by our process chemistry team. Raw materials are sourced from qualified vendors and verified against specification before use. Each batch follows a master batch record with defined critical process parameters, in-process controls, and hold points to ensure consistent quality.

The 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone manufacturing process includes reaction setup, controlled conditions for yield and selectivity, work-up and isolation, purification (crystallization, filtration, or chromatographic steps as required), and drying under validated parameters. In-process samples are tested at defined stages to confirm reaction progress, impurity profile, and intermediate quality before proceeding.

Finished 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone batches undergo comprehensive release testing including identity confirmation, assay, related substances/impurities profiling, residual solvents (ICH Q3C), water content, heavy metals screening, and appearance. Only material meeting predefined specifications and quality standards is approved for release and dispatch.

Our Surat facility supports scale-up from pilot batches to commercial production, enabling seamless transition from development quantities to ongoing supply agreements. Process validation documentation, stability data, and change control records are maintained to support regulatory submissions and customer audits.

Learn more about our manufacturing capabilities and quality assurance systems.

Vubrix Pharma offers flexible packaging options for 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone to suit R&D, pilot, and commercial requirements. Standard packaging includes double-layer polyethylene liners inside HDPE drums or fiber drums, with tamper-evident sealing and clear batch identification labels.

Available pack sizes range from 1 kg and 5 kg laboratory packs to 25 kg and 50 kg commercial drums, with custom packaging configurations available for long-term supply contracts. All packaging materials are selected to protect product integrity during storage and international transit.

Each 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone shipment includes batch-specific documentation: Certificate of Analysis, packing list, and commercial invoice. For regulated markets, we provide additional documentation including manufacturing details, stability summaries, and regulatory support letters as required.

Export shipments are handled with appropriate labeling, hazard classification (where applicable), and compliance with international transport regulations. Our logistics team coordinates FOB, CIF, and door-delivery arrangements based on your preferred Incoterms and destination country requirements.

Store in a tightly closed container, protected from light and moisture, at room temperature (15-30°C).

For long-term storage of 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone, maintain inventory rotation on a first-expiry-first-out (FEFO) basis. Periodic re-testing may be recommended for extended storage periods; contact our technical team for retest interval guidance specific to your storage conditions.

Warehouse facilities at Vubrix Pharma maintain controlled environmental conditions with monitoring systems to ensure product stability from manufacturing through dispatch. Customers are advised to replicate recommended storage conditions upon receipt to preserve 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone quality throughout the supply chain.

Quality is the foundation of every 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone batch produced at Vubrix Pharma. Our quality assurance system encompasses vendor qualification, raw material testing, in-process controls, finished product release testing, stability studies, and complaint handling—all documented under GMP-aligned procedures.

7-Hydroxy-3,4-dihydro-2(1H)-quinolinone is tested against applicable pharmacopoeial standards including USP, EP, and BP monographs where available. Analytical methods are validated or verified for specificity, accuracy, precision, linearity, range, and robustness. Our QC laboratory is equipped with HPLC, GC, KF titrator, UV spectrophotometer, and supporting instruments for comprehensive characterization.

Impurity profiling for 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone follows ICH Q3A/Q3B guidelines for related substances and degradation products. Residual solvent levels comply with ICH Q3C limits. Heavy metal content is controlled within pharmacopoeial specifications. Batch records, analytical data, and deviation investigations are maintained for full traceability.

Vubrix Pharma welcomes customer audits and provides quality agreements, technical questionnaires, and regulatory documentation to support your vendor qualification process. Our commitment to continuous improvement drives ongoing process optimization and quality system enhancements.

Vubrix Pharma exports 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone to pharmaceutical customers across United States, Canada, United Kingdom, Germany, France, Italy, Spain, UAE, Saudi Arabia, Egypt, Brazil, Mexico, India, and additional markets worldwide. Our export experience includes navigating country-specific registration requirements, import documentation, and customs clearance procedures.

For US and EU markets, we provide DMF/CTD support documentation and technical packages to facilitate regulatory submissions. Middle East and African customers benefit from our responsive logistics coordination and documentation tailored to local import regulations.

Latin American markets including Brazil and Mexico are served with complete commercial and technical documentation in English, with support for country-specific regulatory queries. Asian markets leverage our strategic location in Gujarat, India, for efficient supply chain connectivity.

Whether your 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone requirement is for a one-time R&D quantity or a multi-year commercial supply agreement, Vubrix Pharma's export team provides competitive lead times, transparent communication, and reliable delivery schedules.

Choosing Vubrix Pharma as your 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone intermediate manufacturer means partnering with a GMP-certified Indian supplier committed to quality, transparency, and fast response times. We combine technical expertise with commercial flexibility to support your procurement goals.

Our Surat manufacturing facility offers scalable production capacity, from kilogram-scale R&D batches to multi-ton commercial volumes. This scalability eliminates the need to switch suppliers as your 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone requirements grow from development to commercial launch.

Vubrix Pharma provides comprehensive documentation packages including COA, MSDS, stability data summaries, and regulatory support for US FDA, EMA, and other authority submissions. Our technical team responds to specification queries, method transfer discussions, and audit requests promptly.

With competitive pricing, reliable lead times, and a customer-first approach, Vubrix Pharma is the preferred 7-Hydroxy-3,4-dihydro-2(1H)-quinolinone supplier for pharmaceutical companies seeking a dependable long-term manufacturing partner in India. Request a quotation today to experience our responsive service firsthand.